Brief: Novonesis Outlook FY Organic Growth 7-8%
07/11/2024 07:00
Nov 07 (Reuters) - Novonesis outlook FY adjusted EBITDA margin 35.5-36.5%
Recent news on Novozymes A/S
See all newsGivaudan jumps on fragrance outperformance; peers follow
Europe Research Roundup: IWG, Londonmetric, Sartorius
Brief: Novonesis To Build Next Generation Enzyme Production Facility In India
Next cycle in ingredient makers sector belongs to biotech, Jefferies says
Europe Research Roundup: DSM-Firmenich, Merck, Orsted